Alpha 1-antitrypsin deficiency, complement activation, and chronic liver disease. 1991

E T Littleton, and L Bevis, and L J Hansen, and M Peakman, and A P Mowat, and G Mieli-Vergani, and D Vergani
Department of Immunology, King's College School of Medicine and Dentistry, London.

Activation of the complement system, the main humoral mediator of inflammation, is restrained by the action of enzyme inhibitors including alpha 1-antitrypsin. Deficiency leads to chronic liver disease in about one in five children with this genetic defect. Complement activation was investigated in 34 children with alpha 1 AT deficiency (12 with minimal, 10 with moderate, and 12 with severe liver disease) and in 38 sex and age matched normal children by measuring the complement parent molecules C3, C4, the C3d fragment and by calculating the C3d:C3 ratio. C3 and C4 were lower in children with severe liver disease compared with controls, indicating impairment of hepatic protein synthesis or complement consumption. The C3d activation fragment was higher in all the patient groups when compared with controls while the C3d:C3 ratio, a measure of activation independent of the concentrations of the parent molecule, was higher in patients than in controls and increased with the degree of disease severity. These results suggest that complement may have a role in the pathogenesis of the chronic liver disease associated with alpha 1AT deficiency.

UI MeSH Term Description Entries
D007223 Infant A child between 1 and 23 months of age. Infants
D008107 Liver Diseases Pathological processes of the LIVER. Liver Dysfunction,Disease, Liver,Diseases, Liver,Dysfunction, Liver,Dysfunctions, Liver,Liver Disease,Liver Dysfunctions
D008297 Male Males
D010641 Phenotype The outward appearance of the individual. It is the product of interactions between genes, and between the GENOTYPE and the environment. Phenotypes
D002648 Child A person 6 to 12 years of age. An individual 2 to 5 years old is CHILD, PRESCHOOL. Children
D002675 Child, Preschool A child between the ages of 2 and 5. Children, Preschool,Preschool Child,Preschool Children
D002908 Chronic Disease Diseases which have one or more of the following characteristics: they are permanent, leave residual disability, are caused by nonreversible pathological alteration, require special training of the patient for rehabilitation, or may be expected to require a long period of supervision, observation, or care (Dictionary of Health Services Management, 2d ed). For epidemiological studies chronic disease often includes HEART DISEASES; STROKE; CANCER; and diabetes (DIABETES MELLITUS, TYPE 2). Chronic Condition,Chronic Illness,Chronically Ill,Chronic Conditions,Chronic Diseases,Chronic Illnesses,Condition, Chronic,Disease, Chronic,Illness, Chronic
D003167 Complement Activation The sequential activation of serum COMPLEMENT PROTEINS to create the COMPLEMENT MEMBRANE ATTACK COMPLEX. Factors initiating complement activation include ANTIGEN-ANTIBODY COMPLEXES, microbial ANTIGENS, or cell surface POLYSACCHARIDES. Activation, Complement,Activations, Complement,Complement Activations
D003176 Complement C3 A glycoprotein that is central in both the classical and the alternative pathway of COMPLEMENT ACTIVATION. C3 can be cleaved into COMPLEMENT C3A and COMPLEMENT C3B, spontaneously at low level or by C3 CONVERTASE at high level. The smaller fragment C3a is an ANAPHYLATOXIN and mediator of local inflammatory process. The larger fragment C3b binds with C3 convertase to form C5 convertase. C3 Complement,C3 Precursor,Complement 3,Complement C3 Precursor,Complement Component 3,Precursor-Complement 3,Pro-C3,Pro-Complement 3,C3 Precursor, Complement,C3, Complement,Complement, C3,Component 3, Complement,Precursor Complement 3,Precursor, C3,Precursor, Complement C3,Pro C3,Pro Complement 3
D003181 Complement C4 A glycoprotein that is important in the activation of CLASSICAL COMPLEMENT PATHWAY. C4 is cleaved by the activated COMPLEMENT C1S into COMPLEMENT C4A and COMPLEMENT C4B. C4 Complement,C4 Complement Component,Complement 4,Complement C4, Precursor,Complement Component 4,Pro-C4,Pro-complement 4,C4, Complement,Complement Component, C4,Complement, C4,Component 4, Complement,Component, C4 Complement,Pro C4,Pro complement 4

Related Publications

E T Littleton, and L Bevis, and L J Hansen, and M Peakman, and A P Mowat, and G Mieli-Vergani, and D Vergani
July 1977, Polski tygodnik lekarski (Warsaw, Poland : 1960),
E T Littleton, and L Bevis, and L J Hansen, and M Peakman, and A P Mowat, and G Mieli-Vergani, and D Vergani
November 2018, Clinics in liver disease,
E T Littleton, and L Bevis, and L J Hansen, and M Peakman, and A P Mowat, and G Mieli-Vergani, and D Vergani
August 2022, Clinics in liver disease,
E T Littleton, and L Bevis, and L J Hansen, and M Peakman, and A P Mowat, and G Mieli-Vergani, and D Vergani
June 1975, Nutrition reviews,
E T Littleton, and L Bevis, and L J Hansen, and M Peakman, and A P Mowat, and G Mieli-Vergani, and D Vergani
January 2021, Translational gastroenterology and hepatology,
E T Littleton, and L Bevis, and L J Hansen, and M Peakman, and A P Mowat, and G Mieli-Vergani, and D Vergani
January 1994, Digestive diseases (Basel, Switzerland),
E T Littleton, and L Bevis, and L J Hansen, and M Peakman, and A P Mowat, and G Mieli-Vergani, and D Vergani
November 1981, British medical journal (Clinical research ed.),
E T Littleton, and L Bevis, and L J Hansen, and M Peakman, and A P Mowat, and G Mieli-Vergani, and D Vergani
January 1981, Acta medica portuguesa,
E T Littleton, and L Bevis, and L J Hansen, and M Peakman, and A P Mowat, and G Mieli-Vergani, and D Vergani
January 1991, Journal of inherited metabolic disease,
E T Littleton, and L Bevis, and L J Hansen, and M Peakman, and A P Mowat, and G Mieli-Vergani, and D Vergani
October 1982, Lancet (London, England),
Copied contents to your clipboard!